Remix Therapeutics

Our Science
About Us
Join Us
News
Clinical Trials

Our Science
About Us
Join Us
News
Clinical Trials
Contact

Advisor Category: Board of Directors

Jeff Goater

Kevin Bitterman

Michael Rome

Scott Biller

Peter Smith

Matthew Patterson

Linda C. Bain

Maria Koehler

Search

Recent Posts

Remix Therapeutics to Present at Guggenheim Second Annual Healthcare Innovation Conference
Watertown biotech on the hunt for capital after early-stage cancer data
Remix Therapeutics reveals first signs of tumor shrinkage with its small molecule mRNA degrader
Remix Therapeutics™ Announces Positive Preliminary Data from Phase 1 Study of REM-422 in Patients with Adenoid Cystic Carcinoma at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Remix Therapeutics™ to Present Phase 1 Data of REM-422 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Conference in Late-Breaking Oral Presentation

Recent Comments

No comments to show.

Archives

Categories

News
Press Release
Publication

Remix Therapeutics

100 Forge Road
Suite 400
Watertown, USA 02472
781-827-0901

Our Science
About Us
Join Us
News
Clinical Trials
Contact

100 Forge Road
Suite 400
Watertown, USA 02472
781-827-0901

© 2023 Remix Therapeutics, Inc. All Rights Reserved